Dr. Alex Delbridge (left), Dr. Stephanie Grabow, and colleagues found a survival protein being targeted in new anti-cancer drugs is critical for emergency blood cell production. Credit: Walter and Eliza Hall Institute
Blocking key 'survival' proteins is a promising tactic for treating cancer, however new research suggests care should be taken as these proteins are also vital for emergency blood cell production.
Dr Alex Delbridge, Dr Stephanie Grabow and Professor Andreas Strasser from the Walter and Eliza Hall Institute discovered that blood cell production following massive blood cell depletion was fatally compromised when the cell survival protein MCL-1 was depleted.
The research team found that reducing MCL-1 levels hindered recovery of the blood cell system after extensive destruction of mature blood cells, which is a common side-effect of chemotherapy and radiotherapy. Reducing MCL-1 also impaired reconstitution of the bone marrow after blood stem cell transplants, a vital curative treatment for some cancers.
Dr Delbridge said MCL-1 was critical for the survival of many cancer cells, including a number of leukaemias and lymphomas, but also played an important role in normal blood cell production. "Our previous research has shown that targeting MCL-1 could be used with great success for treating certain blood cancers," he said. "However we have now shown that MCL-1 is also critical for emergency recovery of the blood cell system after cancer therapy-induced blood cell loss."
Overproduction of cell survival proteins, such as MCL-1, allows emerging cancer cells to escape from death-inducing signals, enabling the accumulation of further genetic mutations that promote cancer development. Drugs that reduce the activity of 'pro-survival' proteins can kill cancer cells and are a promising therapeutic strategy that is currently being explored.
The research team used a genetic trick to mimic the effect of reducing MCL-1 activity to examine the impact it had on the blood cell system after conventional cancer treatments such as chemotherapy, Dr Delbridge said. "Removing one copy of the gene encoding MCL-1 reduced its concentration, replicating the effects of a partial inhibition by a drug," he said. "We found that reducing MCL-1 protein levels severely impaired recovery of the blood cell system following chemotherapy. This exquisite dependency on MCL-1 for emergency blood cell production has important implications for potential cancer treatments involving MCL-1 inhibitors."
Dr Grabow said many current treatments for blood cancers involved patients being treated with chemotherapy or radiotherapy, sometimes followed by stem cell transplantation to repopulate the bone marrow.
"What we have shown is that, if MCL-1 activity is compromised, a patient would face a significant hurdle in producing new blood cells," she said. "If MCL-1 inhibitors are to be used in combination with other cancer therapies, careful monitoring of the blood cell system will be needed. "The research findings would aid the design of future clinical studies trialling MCL-1 inhibitors, Dr Grabow said. "Our institute colleagues are working to evaluate a potential new drug to treat blood cancers by targeting MCL-1," she said. "Our findings suggest that MCL-1 inhibitors and chemotherapeutic drugs should not be used simultaneously."
Dr Delbridge said the discovery also offered insights for improving stem cell transplantation. "Stem cell transplants can be dangerous because, until the blood cell system is functionally restored, patients are vulnerable to infection," he said. "Our research suggests that increasing levels of MCL-1 or decreasing the activity of opposing proteins could be a viable strategy for speeding up the regeneration process and reducing the risk of infection after stem cell transplantation."
The research was published today in the journal Blood. The study was funded by Cancer Council Victoria, the Lady Tata Memorial Trust (UK), the Leukemia and Lymphoma Society (US), Cancer Therapeutics CRC, National Health and Medical Research Council, The Redstone Foundation and the Victorian Government.
Explore further: 'Survival' protein a target in drug-resistant non-Hodgkin lymphomas
Medical Xpress on facebook
Related Stories
'Survival' protein a target in drug-resistant non-Hodgkin lymphomas
Melbourne researchers have discovered that targeting a cell 'survival' protein could help treat some lymphomas, including those cancers with genetic defects that make them resistant to many existing therapies.
Researchers discover 'milk' protein that enables survival of the species
Australian researchers have discovered the protein MCL-1 is critical for keeping milk-producing cells alive and sustaining milk production in the breast. Without milk production, offspring cannot survive, ...
Survival protein a potential new target for many cancers
Walter and Eliza Hall Institute researchers have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells.
Cell death researchers identify new Achilles heel in acute myeloid leukemia
Melbourne researchers have discovered that acute myeloid leukaemia (AML), an aggressive blood cancer with poor prognosis, may be susceptible to medications that target a protein called Mcl-1.
Researchers study how cancer cells respond to Mcl-1-inhibitory BH3-mimetics
The European pharmaceutical company Servier has established a collaborative partnership with the Walter and Eliza Hall Institute to facilitate the development of new agents that could be effective in treating ...
Recommended for you
Childhood cancer survivors face chronic health problems
The number of childhood cancer survivors in the U.S. has increased, but the majority of those who have survived five or more years after diagnosis face chronic health problems related to their treatment, according to a new ...
Origin of cancer wasting identified in fruit flies
The progressive wasting of muscle and fat tissue throughout the body is one of the most visible and heartbreaking manifestations of cancer, yet little is known about how tumors cause distant tissues to degenerate. ...
Can cancer vaccines prolong survival?
Therapeutic anti-cancer vaccines developed to treat metastatic disease such as advanced prostate cancer or melanoma rarely have a noticeable effect on the tumor but have been associated with a statistically ...
erythropoietin combined with radiation therapy does not improve local-regional control in anemic patients
Long-term analysis of Radiation Therapy Oncology Group (RTOG) 9903 demonstrates that the addition of erythropoietin (EPO) did not improve local-regional control for anemic patients with head and neck squamous ...
Common cancers highjack powerhouses of cells
In a breakthrough in the understanding of how cancer does its deadly work, researchers at the University of Virginia School of Medicine have shown that many cancers - including nearly all pancreatic cancers ...
Elevating the hunt for environmental link to breast cancer
Imagine that you are a molecular biologist who has spent the last 20 years in your lab, doggedly trying to figure out how chemicals in the environment cause human cells to become cancerous. One day a benefactor ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
Dr. Alex Delbridge (left), Dr. Stephanie Grabow, and colleagues found a survival protein being targeted in new anti-cancer drugs is critical for emergency blood cell production. Credit: Walter and Eliza Hall Institute
Blocking key 'survival' proteins is a promising tactic for treating cancer, however new research suggests care should be taken as these proteins are also vital for emergency blood cell production.
Dr Alex Delbridge, Dr Stephanie Grabow and Professor Andreas Strasser from the Walter and Eliza Hall Institute discovered that blood cell production following massive blood cell depletion was fatally compromised when the cell survival protein MCL-1 was depleted.
The research team found that reducing MCL-1 levels hindered recovery of the blood cell system after extensive destruction of mature blood cells, which is a common side-effect of chemotherapy and radiotherapy. Reducing MCL-1 also impaired reconstitution of the bone marrow after blood stem cell transplants, a vital curative treatment for some cancers.
Dr Delbridge said MCL-1 was critical for the survival of many cancer cells, including a number of leukaemias and lymphomas, but also played an important role in normal blood cell production. "Our previous research has shown that targeting MCL-1 could be used with great success for treating certain blood cancers," he said. "However we have now shown that MCL-1 is also critical for emergency recovery of the blood cell system after cancer therapy-induced blood cell loss."
Overproduction of cell survival proteins, such as MCL-1, allows emerging cancer cells to escape from death-inducing signals, enabling the accumulation of further genetic mutations that promote cancer development. Drugs that reduce the activity of 'pro-survival' proteins can kill cancer cells and are a promising therapeutic strategy that is currently being explored.
The research team used a genetic trick to mimic the effect of reducing MCL-1 activity to examine the impact it had on the blood cell system after conventional cancer treatments such as chemotherapy, Dr Delbridge said. "Removing one copy of the gene encoding MCL-1 reduced its concentration, replicating the effects of a partial inhibition by a drug," he said. "We found that reducing MCL-1 protein levels severely impaired recovery of the blood cell system following chemotherapy. This exquisite dependency on MCL-1 for emergency blood cell production has important implications for potential cancer treatments involving MCL-1 inhibitors."
Dr Grabow said many current treatments for blood cancers involved patients being treated with chemotherapy or radiotherapy, sometimes followed by stem cell transplantation to repopulate the bone marrow.
"What we have shown is that, if MCL-1 activity is compromised, a patient would face a significant hurdle in producing new blood cells," she said. "If MCL-1 inhibitors are to be used in combination with other cancer therapies, careful monitoring of the blood cell system will be needed. "The research findings would aid the design of future clinical studies trialling MCL-1 inhibitors, Dr Grabow said. "Our institute colleagues are working to evaluate a potential new drug to treat blood cancers by targeting MCL-1," she said. "Our findings suggest that MCL-1 inhibitors and chemotherapeutic drugs should not be used simultaneously."
Dr Delbridge said the discovery also offered insights for improving stem cell transplantation. "Stem cell transplants can be dangerous because, until the blood cell system is functionally restored, patients are vulnerable to infection," he said. "Our research suggests that increasing levels of MCL-1 or decreasing the activity of opposing proteins could be a viable strategy for speeding up the regeneration process and reducing the risk of infection after stem cell transplantation."
The research was published today in the journal Blood. The study was funded by Cancer Council Victoria, the Lady Tata Memorial Trust (UK), the Leukemia and Lymphoma Society (US), Cancer Therapeutics CRC, National Health and Medical Research Council, The Redstone Foundation and the Victorian Government.
Explore further: 'Survival' protein a target in drug-resistant non-Hodgkin lymphomas
Medical Xpress on facebook
Related Stories
'Survival' protein a target in drug-resistant non-Hodgkin lymphomas
Melbourne researchers have discovered that targeting a cell 'survival' protein could help treat some lymphomas, including those cancers with genetic defects that make them resistant to many existing therapies.
Researchers discover 'milk' protein that enables survival of the species
Australian researchers have discovered the protein MCL-1 is critical for keeping milk-producing cells alive and sustaining milk production in the breast. Without milk production, offspring cannot survive, ...
Survival protein a potential new target for many cancers
Walter and Eliza Hall Institute researchers have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells.
Cell death researchers identify new Achilles heel in acute myeloid leukemia
Melbourne researchers have discovered that acute myeloid leukaemia (AML), an aggressive blood cancer with poor prognosis, may be susceptible to medications that target a protein called Mcl-1.
Researchers study how cancer cells respond to Mcl-1-inhibitory BH3-mimetics
The European pharmaceutical company Servier has established a collaborative partnership with the Walter and Eliza Hall Institute to facilitate the development of new agents that could be effective in treating ...
Recommended for you
Childhood cancer survivors face chronic health problems
The number of childhood cancer survivors in the U.S. has increased, but the majority of those who have survived five or more years after diagnosis face chronic health problems related to their treatment, according to a new ...
Origin of cancer wasting identified in fruit flies
The progressive wasting of muscle and fat tissue throughout the body is one of the most visible and heartbreaking manifestations of cancer, yet little is known about how tumors cause distant tissues to degenerate. ...
Can cancer vaccines prolong survival?
Therapeutic anti-cancer vaccines developed to treat metastatic disease such as advanced prostate cancer or melanoma rarely have a noticeable effect on the tumor but have been associated with a statistically ...
erythropoietin combined with radiation therapy does not improve local-regional control in anemic patients
Long-term analysis of Radiation Therapy Oncology Group (RTOG) 9903 demonstrates that the addition of erythropoietin (EPO) did not improve local-regional control for anemic patients with head and neck squamous ...
Common cancers highjack powerhouses of cells
In a breakthrough in the understanding of how cancer does its deadly work, researchers at the University of Virginia School of Medicine have shown that many cancers - including nearly all pancreatic cancers ...
Elevating the hunt for environmental link to breast cancer
Imagine that you are a molecular biologist who has spent the last 20 years in your lab, doggedly trying to figure out how chemicals in the environment cause human cells to become cancerous. One day a benefactor ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment